2026 Q3
Category: Myvac
Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
2026 Half Year results
Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line
ProBioGen
A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial
C. Ottensmeier, et al. Article available on Nature Communications website – Download the Article
Transgene expands myvac®into NSCLC with TG4070
link to webcast
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
TG4070
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
TG4050
TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment
K. Bidet-Huang World Vaccine Congress 2026 – Download the Oral Presentation
2025 Full-year results and business update
link to webcast
Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
medRxiv 2026